Thursday, 16 January 2020

Brain Dead Diagnosis and Treatment Industry Overview, Trends and Market Growth Analysis Research Report 2023

Brain Dead Diagnosis & Treatment Research Report: By Diagnosis Type (Physical Examination, Blood Test, Brain Scans) Brain Scans (CT, MRI, EEG) Treatment (Medical Treatment) End User (Hospitals & Clinics, Research Laboratories) - Global Forecast till 2023
Market Scenario
The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the global brain dead diagnosis and treatment market.
A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global market of brain dead diagnosis and treatment is expected to grow at a CAGR of approximately 7% during the forecast period 2017-2023.
Intended Audience
  • Brain Dead Diagnosis and Treatment Suppliers
  • Brain Dead Diagnosis and Treatment Trends
  • Brain Dead Diagnosis and Treatment Manufacturers
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities
Segmentation
The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography
On the basis of treatment, it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Key Players in the Global Brain Dead Diagnosis and Treatment Market    
Some of key the players in the Global Brain dead diagnosis and Treatment Market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others
Regional Analysis
The global brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.
Europe holds the second position in the global brain dead diagnosis & treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.
Asia Pacific is the fastest growing brain dead diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region. 
Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Posted by at No comments:

Coma Diagnosis and Treatment Market Growth Opportunities, Analysis and Forecasts Report 2019-2023

Coma Diagnosis & Treatment Market Research Report: By Types (Toxic-Metabolic Encephalopathy, Anoxic Brain Injury), Diagnosis (Physical Examination, Brain Scans) Treatment (Medical Treatment), End User (Hospitals & Clinics) - Global Forecast till 2023
Market Scenario
Coma refers to a state of unconsciousness in which a patient remains unresponsive to anything around them for a prolonged period of time. Depending on the severity of the coma, patient may require life-saving resuscitative measures and once the patient is medically stable, treatments can be used to treat original problem that is causing the coma.
There is no particular treatment that can cause someone to come out of a coma and treatments can prevent further physical and neurological damage. However depending on the cause of a coma, patient who are continuosly in this state for more than one year are extremely unlikely to awaken.
Increasing prevalence of neurological disorders, increasing investment by biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the Coma Diagnosis and Treatment Market Size. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of diseases will fuel the market growth during the forecast period
Over the last decade, the number of hospitals has increased to a great extent, which has influenced the growth of the market positively. Moreover, increasing demand for better treatment and changing reimbursement policies have fueled the market growth.
According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.
The global coma diagnosis & treatment market is expected to grow at a CAGR of ~7.1% during the forecast period 2017-2023. 
Key Players
  • GE Healthcare (U.S.)
  • Siemens Healthcare(U.S.)
  • Philips Healthcare (U.S.)
  • Carestream Health (U.S.)
  • Electrical Geodesics Inc. (U.S.)
  • Masimo Corporation (U.S.)
  • Hologic (U.S.)
  • Shimadzu Corporation (Japan)
  • Toshiba Medical Systems Corporation (Japan)
  • Fujifilm Holdings (Japan)
  • Nihon Kohden Corporation (Japan)
  • Esaote (Italy)

Regional Analysis
Asia Pacific is the fastest growing coma diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.  
The Americas dominate the global coma diagnosis & treatment market owing to well-developed technology, increasing patient population for brain disorder, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Europe holds the second position in the global coma diagnosis & treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.     
Segmentations
The global coma diagnosis & treatment market is segmented on the basis of types, diagnosis, treatment, and end user.
On the basis of diagnosis it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG).
On the basis of the type, it is segmented into toxic- metabolic encephalopathy, anoxic brain injury, persistent vegetative state, locked-in syndrome, and brain death.  
On the basis of treatment it is segmented into medical treatment, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.
Posted by at No comments:

Neuropathology Market 2019 Global Key Vendors Analysis, Revenue, Trends & Forecast to 2023

Neuropathology Market Research Report By Diagnosis (Biopsy, Body Fluids, Peripheral Blood Smears, others), Application (Cerebral Hypoxia & Stroke, Perinatal Disorders, CNS Infections, Demyelinative Diseases, others), End User– Global Forecast till 2023
Market Synopsis of the Global Neuropathology Market
Neuropathology pertains to the aliment of nerves reculting in pain and numbness of the limbs and it is gaining prominence in this market. The increasing incidence of musculoskeletal conditions and technological advancements in medical diagnostic devices are some factors responsible for the growth of the global neuropathology market size.
The number of patients suffering from cerebrovascular disorders has increased rapidly and has reached an all-time high in the past few years. There has been a significant rise in the number of surgeries associated with the treatment of such disorders. As the neurosurgeries and spinal surgeries are very critical, continuous monitoring during the whole procedure proves to be beneficial as the information about the electrical signals in brain and the nerves can be obtained in real time.
The Global market of Neuropathology is expected to grow at a CAGR of approximately 6% during the forecast period 2019-2023.
Biopsies primarily consist of the skin. The recently developed neuropathy test, the epidermal nerve fiber density testing (ENFD) in which the nerve fibers of the skin is analysed by performing a  punch skin biopsy to identify small fiber neuropathies. This pathology test is becoming available in selected labs as well as a few universities; it replaces the traditional sural nerve biopsy test and is less invasive. It is used to identify painful small fiber neuropathies.
According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases. Many healthcare professionals have started using these diagnostics techniques, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for Neuropathology.
Key Players
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
  • ARUP Laboratories
  • Therapath LLC
  • Abbott Laboratories
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd.
  • Sakura Finetek USA Inc.
  • Danaher Corporation
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.N
  • NeoGenomics Laboratories
Segmentation
The Neuropathology is segmented on the basis of diagnosis test, application, and end-users.
On the basis of diagnostic test, the market is segmented into the biopsy, body fluids, peripheral blood smears, tissue resections, and others 
The biopsy sub-segment is divided into Epidermal nerve fiber density testing (ENFD), Sural nerve biopsy test, bone-marrow biopsies, lymph-node biopsies and others
On the basis of product, the application market is segmented into cerebral hypoxia and stroke, perinatal disorders, CNS infections, demyelinative diseases, brain tumors, neurodegenerative diseases, inherited metabolic disorders, peripheral neuropathy, and myopathology
On the basis of end-user, the market is segmented into hospitals, clinics, research centers and others.
Regional Analysis
The Global Neuropathology Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global neuropathology market owing to the increasing healthcare expenditure in North America since 2016. U.S. has some of the best hospitals in the world with state of the art infrastructure. Most of the hospitals and their neurology departments are well equipped with the equipment that is required for the working of the neuropathology techniques. Various organizations and private companies are engaged in the activities of spreading awareness about the benefits of the neuropathology test among common people through various educational and marketing ways. As a result, huge numbers of people are opting for the neuropathology tests as a point of care. The country has been developing number of academic courses to develop skilled personnel in the neuropathology field over the years. Hence the availability of the neuropathology specialists in North American countries is high.
Europe is the second largest market for neuropathology market. For Europe, the neuropathology market including the brain tumors market is regarded as a strong competitive market. European countries are now making efforts in promoting the benefits of the intraoperative neurophysiological monitoring services. Patient friendly healthcare and insurance policies are making a positive impact on the people taking medical assistance.
Asia Pacific is the fastest growing region over the forecast period. The healthcare spending in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
he connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease disorder market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
  • Abbott Laboratories
  • Bayer AG
  • Hoffmann-La Roche Ltd
  • Pfizer
  • AutoImmune Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Biogen
  • LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Posted by at No comments:

Connective Tissue Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 – 2023


Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2023
Connective tissues are a group of cellular congregations that provide support and structure to the human body. Connective tissue disease is a group of disorders which involves these protein rich tissues. Protein rich tissues play an important role of supporting organs and other parts of the body. Connective tissue disorders involves multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels. More than 200 disorders affect the connective tissues. According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population. It is also reported that among Asian population, the condition is more prevalent in China, and Japan. In the European region, the disorder is more prevalent in Italy, Hungary, Norway, and Poland.
Developments in the treatment of connective tissue diseases (CTDs) have been improved considerably, and the global connective tissue disease disorder market is slated to grow at a promising CAGR of 11.5% over the forecast period of 2017-2023. The cause of the disease is unknown and there's no cure for connective tissue disease yet, but medications are present to manage the signs and symptoms. CTDs include a large number of disorders which can affect different organs of the body. There is broad variability in disorders among patient suffering from CTDs.
It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.
A significant increase in the research and development efforts to find treatment and cure for CTDs have aided the growth of the market. Various therapy trials are underway which have been able to identify promising novel approaches to treat CTDs and are expected to boost the growth of the market. Rising prevalence of CTDs across the globe, especially in women has propelled the growth of the market. Additionally, support from governments across the world along with funds for R&D from the private industry is also a key driver of the growth of the market. With the increase in awareness and acceptance among the general population about connective tissue diseases, the diagnosed and drug-treated population will increase which will positively impact the market. Rising expenditure on healthcare, high unmet medical needs of the current treatment and growing prevalence of CTDs in Asia and Africa are expected to promote the growth of the market.  However, the growth of the market might be hindered by lack of a knowledgeable workforce, inadequate research and development infrastructure, lack of funds in middle and low-income countries.
Key Players
Some of key the players in the market are
·         Abbott Laboratories
·         Bayer AG
·         F. Hoffmann-La Roche Ltd
·         Pfizer
·         AutoImmune Inc.
·         Johnson & Johnson
·         Amgen Inc.
·         AstraZeneca
·         Eli Lilly and Company
·         Biogen
·         LUPIN
Segmentation
The connective tissue disease market is segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, market is segmented into physical examination, X-ray examination, ANA (Antinuclear Antibody Test), and others.
On the basis of treatment, market is classified into non-steroidal anti-inflammatory drugs (NSAIDs), cortisone drugs/steroids, antimalarial drugs, cytotoxic drugs, and others
On the basis of end-user, market is segmented into hospital, diagnostic clinics, and others.
Regional Analysis
The Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure. As per the facts suggested by the Centers for Disease Control and Prevention (CDC), out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.
Europe holds the second position in the connective tissue disease market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe.
Asia Pacific is the fastest growing market connective tissue disease, owing to a huge patient pool, developing healthcare technology, and rising healthcare expenditure in some countries within this region. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for connective tissue disease due to lack of technical knowledge and poor medical facilities. 
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Posted by at No comments:

Augmented Bone Graft Industry Overview, Trends and Market Growth Analysis Research Report 2023

Augmented Bone Graft Market Research Report by product (Allografts, Bone Grafts Substitutes, Cell-based Matrices), application (Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, Spinal Fusion), end user– Global forecast till 2023
According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.
The Global market of Augmented Bone Graft is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.
Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.
Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.
There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.
Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.
Additionally, stringent regulations obstruct the growth of augmented bone grafts market size and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.
The Key Players
  • Zimmer Holdings, Inc.
  • BioMimetic Therapeutics LLC
  • Wright Medical Technology, Inc.
  • Stryker Corporation, Smith & Nephew Plc
  • RTI Surgical, Inc.,
  • Olympus Biotech Corporation
  • NuVasive, Inc.
  • NovaBone Products LLC
  • Medtronic, Inc.
  • LifeNet Health, Inc.
  • Integra LifeSciences Holdings Corporation
  • Exactech, Inc.
  • DePuy Spine, Inc.
  • Synthes Inc.
  • DePuy Synthes Companies
  • Biomet, Inc.
Segmentation
The Augmented Bone Graft is segmented on the basis of products, application, and end-users.
On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion
On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.
On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.
Regional Analysis
The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.
For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.
Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.
Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.
Posted by at No comments:

Oral Thrush Market Size, Share, Global Analysis, Growth Opportunities, Key Driven Factors, Healthcare Industry Highlights Forecast to 2023

Oral Thrush Market Information: By Type (Pseudomembranous, Erythematous, Hyperplastic, others), Diagnosis (Examination, Biopsy, Endoscopy, others), Treatment (Anti-Fungal, Immune-Modulators), End User (Hospitals & Clinics) - Global Forecast Till 2023
Market Scenario
Oral thrush also called as oral candidiasis is an infection of the mouth caused by strains of the Candida species. Candida albicans is the most commonly implicated organism, which occurs naturally in about 50% of the world's population as a normal component of the oral microbiota. However, Candida albicans is an opportunistic pathogen and it accounts for about 50% of oral candidiasis cases across the globeand  other strains of candida such as C. tropicalis, C. glabrata and C. albicans, account for over 80% of cases collectively. Increasing prevalence of  HIV has increased immunodeficiency in the patient, which makes the patient more susceptible to dubliniensis and C. geotrichium. Furthermore, the infection is also detected in hospitalized patients, smokers, immune-compromised individuals due to diseases such as diabetes, cancer, and Down syndrome.
Apart from common Oral Thrush symptoms such as white layer of infection on the tongue and other parts of oral mucosa, it includes burning sensation, metallic, acidic, salty or bitter taste in the mouth, difficulty swallowing (dysphagia), and hoarseness of the voice etc.
Various factors affects the prevalence of Candida such as high humidity, and temperature. Females are more prone to develop the condition as compared to males. Moreover, people wearing dentures, consumption of high  carbohydrates containing diet, suffering from xerostomia (dry mouth) are at a higher risk of developing oral thrush. Other factors affecting the market for oral thrush is age with newborns and aged population having the least prevalence while infants having the highest.
Market development represents the best strategy for the market growth. The market will witness exponential growth over the review period owing to advanced antibacterial mouth rinses and improving palatability and quality of oral hygiene products. The developing regions of Asia and the Middle East are attracting new players owing to less regional competition for the oral thrush product. Increase in risk factors such as high fat containing and sugar rich foods, growing screening, increasing infant population. On the other hand, the market may experience a slow growth on account of lack of awareness and misdiagnosis of the disease.
The global oral thrush market is expected to reach USD 9.5 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.4 % during the forecast period 2017-2023.
Key Players in the Global Oral Thrush Market
Some of key players profiled in the report are Bayer AG, Teva Pharmaceuticals, Stellar Pharma, Pfizer Inc., Wockhardt Ltd., Ranbaxy Laboratories Limited, Bristol Laboratories, Glenmark Pharmaceuticals, GlaxoSmithKline Plc., and others.
Segmentation:
The global oral thrush market has been segmented on the basis of type, diagnosis, treatment, and end user.
Based on type, the market has been segmented as pseudomembranous, erythematous, hyperplastic, and others.
Based on diagnosis, the market has been segmented as examination, biopsy, endoscopy, and others.
Based on treatment, the market has been segmented as anti-fungal, immune-modulators, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Regional Analysis
Globally, the North America market dominates the Oral Thrush market. Factors such as the well-spread awareness among people towards the oral hygiene and healthcare along with the extensive use of medications and high expenditure on the health care and augmenting uptake of new products primarily in the US drive the market growth in the region.
The Europe market accounts for the second-largest market for Oral Thrush owing to the proliferation of healthcare sector, the presence of well-established players and growing healthcare expenditures in the region. Indeed, the resurging economy is the main driving force increasing the market value in the region.
Simultaneously, the presence of the leading global players in the region is some of the key factor substantiating the growth of the regional market. Witnessing a widening uptake of oral hygiene products across the region, the North America market for Oral Thrush is likely to continue its dominance throughout the assessment period.  The North American market significantly contributing to the GDP is expected to register a significant CAGR during the forecast period.
The Europe healthcare industry is currently booming given the increasing number of medical professionals and growing awareness in the region. Moreover, the high influence of media and the rise in the awareness regarding oral hygiene especially in the countries such as Germany and France drive the European oral thrush market.
The Asia Pacific Oral Thrush market emerging as the fastest growing market accounts for a substantial market share on the global platform. Factors such as the proliferation of healthcare sector in populous countries such as India and China substantiate the market growth in the region. 
Furthermore, factors such as augmenting demand for high standards and high-quality oral care products along with the growing technological advancement are estimated to increase the market scope, boosting the demand for effective oral care treatments in the region.
Posted by at No comments:
Labels:

Homeopathic Medicine Market: 2019 Global Size, Trends, Investments, Share, Leading Players, Merger, Acquisition, Growth Factors, Regional Analysis, And Industry Forecast To 2023

The market for homeopathy has expanded remarkably because of the increasing demand for natural remedies. Growing prevalence of chronic and lifestyle-related diseases such as obesity, diabetes, cancer, and fertility issues have led to a faster adoption of alternative medical treatments such as homeopathic medicine. However, the market is regulated by strict laws pertaining to the application of homeopathy in some developed nations like the U.K. and Germany. Meanwhile, many developing economies pose a high possibility for development attributing to the cultural propinquity for natural medication.
The Worldwide Homeopathic Medicine Market is expected to grow at a CAGR of 12.5% during the forecast period. The global homeopathic medicine market is expected to show sharp growth over the forecast period. Rising prevalence of chronic disease and increasing demand for medicines from natural sources and overall increase in the awareness about medicines and treatment options in homeopathy drive the market growth. Furthermore, homeopathy is gaining attention in many of the emerging market throughout the globe. Lack of awareness about homeopathy in developing countries may act as a barrier for the market growth.
Growing incidences of lifestyle-related and chronic diseases such as cancer, diabetes, obesity, and fertility problems have led to the increased adoption of alternative medical treatments such as homeopathic medicine, this driving market demand. The homeopathic medicine market is restrained by the implementation of strict regulations surrounding the use of homeopathy in certain developed economies such as Germany and the U.K. Meanwhile; emerging economies carry a high potential for growth due to the cultural affinity for natural medication in several fast emerging markets.
Regional Analysis
Led by the U.S, the Americas account for the largest share of the global market due to the high awareness regarding homeopathic medicine. Highly expensive healthcare often encourages patients to adopt homeopathic medicine. Moreover, the region is witnessing a rising occurrence in lifestyle-related diseases which further facilitate increased demand for homeopathic medicine.
Europe accounts for the second largest share due to the high number of homeopathic practitioners available in the region. U.K leads the regional market with the most significant share. The European region has widespread use of homeopathic medicine for day to day use in assisting the treatment of minor health problems.
In Asia Pacific, rising demand for alternative medicine such as homeopathy and Ayurveda, the prevalence of chronic diseases such as diabetes and obesity and increasing in the adoption of medicines from natural sources drive the market growth. Homeopathic Medicine Market Size in India is the largest for in Asia Pacific owing to its largest homeopathic infrastructure in the world and increasing in the number of homeopathic medical institutes and research centers.  Japanese Homoeopathic Medical Association is engaged in the academic research, promotion and international exchange of homoeopathy in Japan. Whereas, homeopathy is relatively unknown and moderately practiced in China.
Key Players
The competitive analysis of the market in MRFRs report records the strategies and market positions of leading market players such as Natural Health Supply, Boiron, HomeoLab USA, Hyland's Homeopathic, SBL, Nelson & Co. Ltd., and Hahnemann Laboratories Inc.
Latest Industry News
  • NHS funded homeopathic treatments have been cut off with exceptions to be considered on a case by case basis.
  • Indian homeopathy start-up Welcomecure has raised undisclosed investment from Bollywood Thier association with the brand is expected to increase demand.
Market Segmentation
The global homeopathic medicine market is segmented on the basis of type, indication, and end users.
On the basis of drugs, market is segmented into plants based, animal based and mineral based. Plant based is further segmented into Arnica montana, Bryonia alba, Cinchona officinalis, Pulsatilla nigricans, Rhus tox, Symphytum. Animal based is further segmented into Latrodectus mactans, Tarentula Hispania, Tarentula cubensis, Naja tripudians, Vipera, Sepia, and Cantharis. Mineral based is further segmented into Calcarea carbonica, Phosphorus, Calcarea phosphorica, Natrum muriaticuma and others. Other segments are Nosodes, Sarcodes and Imponderabilia.
On the basis of application, the market is segmented into skin & hair, reproductive health, lifestyle disorders, bones, joints, and muscles diseases, brain and nerves disorders, respiratory diseases, childhood diseases, hormonal disorders and others.
On the basis of end user, the market is divided into hospitals, homeopathic clinics, and others.
Posted by at No comments:
Subscribe to: Posts (Atom)